Sendra Luis, Herrero María José, Aliño Salvador F
Pharmacology Department, Faculty of Medicine, Universidad Valencia, Av. Blasco Ibáñez 15, 46010 Valencia, Spain.
Pharmacogenetics Unit, Instituto de Investigación Sanitaria La Fe, Av. Fernando Abril Martorell 106, 46026 Valencia, Spain.
Genes (Basel). 2018 Mar 1;9(3):136. doi: 10.3390/genes9030136.
Hydrodynamic gene delivery has proven to be a safe and efficient procedure for gene transfer, able to mediate, in murine model, therapeutic levels of proteins encoded by the transfected gene. In different disease models and targeting distinct organs, it has been demonstrated to revert the pathologic symptoms and signs. The therapeutic potential of hydrofection led different groups to work on the clinical translation of the procedure. In order to prevent the hemodynamic side effects derived from the rapid injection of a large volume, the conditions had to be moderated to make them compatible with its use in mid-size animal models such as rat, hamster and rabbit and large animals as dog, pig and primates. Despite the different approaches performed to adapt the conditions of gene delivery, the results obtained in any of these mid-size and large animals have been poorer than those obtained in murine model. Among these different strategies to reduce the volume employed, the most effective one has been to exclude the vasculature of the target organ and inject the solution directly. This procedure has permitted, by catheterization and surgical procedures in large animals, achieving protein expression levels in tissue close to those achieved in gold standard models. These promising results and the possibility of employing these strategies to transfer gene constructs able to edit genes, such as CRISPR, have renewed the clinical interest of this procedure of gene transfer. In order to translate the hydrodynamic gene delivery to human use, it is demanding the standardization of the procedure conditions and the molecular parameters of evaluation in order to be able to compare the results and establish a homogeneous manner of expressing the data obtained, as 'classic' drugs.
流体动力学基因递送已被证明是一种安全有效的基因转移方法,在小鼠模型中能够介导转染基因编码蛋白质达到治疗水平。在不同的疾病模型和针对不同器官的研究中,已证明它能逆转病理症状和体征。流体转染的治疗潜力促使不同团队致力于该方法的临床转化。为了防止因快速注射大量液体而产生的血流动力学副作用,必须调整条件,使其适用于大鼠、仓鼠和兔子等中型动物模型以及狗、猪和灵长类等大型动物。尽管为适应基因递送条件采取了不同方法,但在这些中型和大型动物中获得的结果均不如在小鼠模型中取得的结果。在这些减少使用液体量的不同策略中,最有效的方法是避开靶器官的脉管系统并直接注射溶液。通过在大型动物中进行导管插入术和外科手术,这一方法已使组织中的蛋白质表达水平接近金标准模型中的水平。这些有前景的结果以及采用这些策略来转移能够编辑基因的基因构建体(如CRISPR) 的可能性,重新激发了人们对这种基因转移方法的临床兴趣。为了将流体动力学基因递送应用于人体,需要对操作条件和评估分子参数进行标准化,以便能够比较结果并建立一种统一的方式来表达所获得的数据,就像 “经典” 药物那样。